AUBE00 for advanced solid tumors with KRAS mutation
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental drug called AUBE00 for people with solid tumors that have a KRAS mutation, after other treatments have failed. It aims to see if the drug is safe and can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a KRAS mutation in your tumor (confirmed by a lab test).
- Your previous cancer treatments have stopped working, or there are no standard options left.
- You are able to take care of yourself (ECOG score 0 or 1, meaning no major limitations).
- You do not have active brain tumors that require treatment.
- You do not have serious heart problems or a recent stroke/mini-stroke.
- You are not pregnant, breastfeeding, or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
This trial tests a new drug called QTX3034 in people whose cancer has a specific genetic change called KRAS G12D. The drug aims to block the mutated protein that helps cancer grow, and may work even if other treatments have stopped working.
This early-stage study tests a new drug called BAY 3771249 in people with advanced colorectal cancer that has a specific genetic change (KRAS G12D mutation). Researchers want to learn if it's safe and whether it helps shrink tumors.
This trial tests a new drug called JAB-23E73 for people with advanced solid tumors that have a specific change in the KRAS gene. It may be an option if previous treatments have stopped working or are not suitable.
This trial tests a combination of a targeted antibody (cetuximab beta) with a type of radiation and immunotherapy for people with advanced solid tumors that have the EGFR protein. It is for patients who have tried other treatments without success.
This trial tests cetuximab combined with dabrafenib and tislelizumab in people with advanced colorectal cancer that has a BRAF V600E mutation. It’s for cases where the first standard treatment didn’t work or couldn’t be tolerated, aiming to shrink tumors and improve control of the disease.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.